Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT03669653

Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Ischemic Stroke

he purpose of this study is to determine the efficacy and safety of remote ischemic conditioning for acute ischemic stroke.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

First Hospital of Jilin University

Changchun, Jilin, 130000, China

Location contact

Yi Yang, MD, PhD

CONTACT

[email protected]

About this study

In this study, 912 cases of ischemic stroke in 48 hours were included in 5 centers in China according to the principle of random, double-blind and parallel control .The experimental group receive basic treatment and remote ischemic conditioning for 200mmHg, 2 times per day for 7 consecutive days .The control group receive basic treatment and remote ischemic conditioning control for 60mmHg, 2 times per day, 7 days in a row . Two groups will be followed up for 90 days to evaluate the efficacy and safety of remote ischemic conditioning therapy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1)Age≥18 years, < 80 years, regardless of sex;
  • 2)Patients with clinically definite diagnosis of acute ischemic stroke and able to commence RIC treatment within 12 hours of stroke onset
  • 3)Baseline NIHSS score>5, and≤25 ;
  • 4)GCS score ≥8;
  • 5)Signed and dated informed consent is obtained

Exclusion criteria

  • 1) Patients with suspected posterior circulation infarction;
  • 2) Patients who undergo thrombolytic therapy or endovascular treatment;
  • 3) mRS≥2 score before the onset of the disease;
  • 4) Double upper limbs or lower limbs paralysis was found in this case;
  • 5)Active bleeding of organs within 6 months of admission or current, including cerebral hemorrhage, subarachnoid hemorrhage, gastrointestinal hemorrhage, fundus hemorrhage and so on;
  • 6) Other intracranial lesions, such as cerebrovascular malformation cerebral venous diseases, tumor and other diseases involving the brain;
  • 7) Treated blood pressure ≤90mmHg/60mmHg or≥180mmHg/100mmHg;
  • 8) Severe organ dysfunction or failure;
  • 9) Persons suffering from severe hematological diseases or severe coagulation disorder dysfunction;
  • 10) Those who had a history of severe trauma or had major surgery within 6 months prior to admission;
  • 11) The patients who had the contraindication of remote ischemic conditioning treatment, such as severe soft tissue injury, fracture or vascular injury in the upper limb;Acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc;
  • 12) Pregnant or lactating women;
  • 13) Previous remote ischemic conditioning therapy or similar treatment;
  • 14) Patients with a life expectancy of less than 3 months or patients unable to complete the study for other reasons;
  • 15) Severe hepatic and renal dysfunction
  • 16) Unwilling to be followed up or treated for poor compliance;
  • 17) He/She is participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to admission;
  • 18) Other conditions that the researchers think are not suitable for the group.

Treatment and study plan

Remote Ischemic conditioning

Procedure

Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 200 mm Hg. RIC will be conducted twice daily for 7 days.

Sham remote ischemic conditioning

Procedure

Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of healthy upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by inflations of a blood pressure cuff to 60 mm Hg. RIC will be conducted twice daily for 7 days.

Primary outcomes

  1. Proportion of patients with Modified Rankin Scale (mRS) Score 0-2

    Time frame: 3 months

    The primary outcome measure of efficacy is the modified Rankin Scale (mRS) dichotomized to define good functional outcome as mRS 0-2 at 90 days.score, dichotomized to define good functional outcome as mRS 0-2 at 90 days.

Secondary outcomes

  1. NIHSS Score at end of 7th day of treatment

    Time frame: 7 days

    NIHSS Score at end of 7th day of treatment

  2. mRS Score at end of 7th day of treatment

    Time frame: 7 days

    mRS Score at end of 7th day of treatment

  3. Barthel Index at end of 7th day of treatment

    Time frame: 7 days

    Barthel Index at end of 7th day of treatment

  4. Changes of hematological indicators

    Time frame: 48h; 7days

    The changes of hematological indicators (inflammatory cytokine,et al.) between the first 48h and end of 7th day of treatment.

Study contacts

Contact information is provided by the study sponsor or research team.

Yi Yang, MD, PhD

CONTACT

[email protected]

0086-13756661217

Zhen-Ni Guo, MD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Yi Yang

Other

Registry information

Acronym: SERIC-AIS

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Sep 13, 2018
Registry last updated
Oct 2, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.